NPlate

Immune Thrombocytopenia (ITP)

Nplate is prescribed for adults and children 1 year of age and older who have chronic immune thrombocytopenia (ITP). This condition occurs when the immune system destroys platelets, leading to a high risk of bruising and bleeding. It is generally used when other treatments, such as steroids, immunoglobulins, or spleen removal, have not been effective.

The medicine works by helping the body produce more platelets. The objective of treatment is to maintain a platelet count that reduces the risk of bleeding, rather than achieving a completely normal platelet level.

Acute Radiation Syndrome

Nplate is also used to improve survival in people who have been exposed to high doses of radiation, known as hematopoietic syndrome of acute radiation syndrome (HS-ARS). High levels of radiation can damage the bone marrow, preventing it from making enough blood cells.

Limitations of Use

Nplate is not used to treat low platelet counts caused by other conditions, such as myelodysplastic syndrome (MDS). It is specifically indicated for chronic ITP and acute radiation exposure.

Stimulating Platelet Production

NPlate belongs to a class of medications known as thrombopoietin (TPO) receptor agonists. Its primary function is to increase the number of platelets in the blood. Platelets are small blood cells that are essential for blood clotting and stopping bleeding.

Mimicking Natural Proteins

In the body, a natural hormone called thrombopoietin regulates the production of platelets. This hormone attaches to specific receptors on cells in the bone marrow called megakaryocytes. These cells are the precursors to platelets; when they are stimulated by thrombopoietin, they grow and produce new platelets.

Mechanism of Action

NPlate is a protein that is engineered to work in the same way as natural thrombopoietin. When NPlate is injected, it performs several key steps:

• Binding: It travels to the bone marrow and binds to the TPO receptors on the surface of megakaryocytes.
• Activation: This binding activates the cells, signaling them to mature and increase their output of platelets.
• Production: As a result, the bone marrow produces more platelets, which then enter the bloodstream.

It is important to note that NPlate does not stop the body from destroying platelets, which is a common issue in conditions like immune thrombocytopenia (ITP). Instead, it works by boosting the production of new platelets to help maintain a safer level in the blood.

Common Side Effects

The most common side effects reported by people taking NPlate include:

• Headache
• Joint or muscle pain
• Dizziness
• Trouble sleeping
• Stomach pain or indigestion
• Nausea or diarrhea
• Cough or sore throat
• Tingling or numbness in the hands or feet

Serious Side Effects

NPlate may cause serious side effects that require medical attention. These include:

• Blood clots: There is an increased risk of blood clots in the veins or arteries, which can lead to complications like stroke, heart attack, or pulmonary embolism.
• Bone marrow changes: Long-term use may cause reticulin fiber buildup in the bone marrow, potentially affecting blood cell production.
• Worsening of blood conditions: In patients with myelodysplastic syndromes (MDS), NPlate may increase the risk of the condition progressing to acute myeloid leukemia (AML).
• Rebound low platelets: After stopping NPlate, platelet counts may drop lower than they were before treatment, which increases the risk of bleeding.
• Severe allergic reactions: Symptoms may include swelling of the face, rash, or difficulty breathing.

Bone Marrow Changes

Treatment with NPlate may lead to an increase in reticulin fibers within the bone marrow. While these changes may improve after stopping the medication, they can potentially lead to a condition called myelofibrosis. Healthcare providers monitor blood tests regularly to check for signs of these changes.

Blood Clotting Risks

There is a risk of developing blood clots when taking NPlate, especially if the platelet count becomes too high. These clots can occur in the blood vessels of the heart, brain, lungs, or limbs. The risk may be higher in patients with known risk factors for blood clots or chronic liver disease.

Progression of Myelodysplastic Syndromes

NPlate is not intended for use in patients with Myelodysplastic Syndromes (MDS) or other types of blood cancer. Clinical studies have shown that NPlate may increase the risk of MDS progressing to acute myeloid leukemia (AML), a more aggressive form of blood cancer.

Loss of Response

In some cases, the body may develop antibodies against NPlate, which can cause the medication to stop working. If platelet counts do not increase or if they drop significantly during treatment, a healthcare provider may perform tests to determine if antibodies have formed.

Risks After Discontinuing Treatment

If NPlate is stopped, platelet counts may drop below the levels recorded before treatment began. This can increase the risk of serious bleeding. Monitoring usually continues for several weeks after the final dose to ensure safety.

Pregnancy

Data regarding the use of NPlate in pregnant women are limited. In animal studies, the active ingredient was shown to cross the placenta and impact fetal platelet counts. Due to these findings, healthcare providers generally advise using NPlate during pregnancy only when the clinical need is clear and alternative treatments are not suitable.

If you are pregnant or planning to conceive, it is important to discuss your treatment options with your doctor to understand the potential risks to the pregnancy.

Breastfeeding

It is not known if NPlate is present in human breast milk. Because of the potential for serious adverse reactions in a nursing child, a decision must be made whether to discontinue breastfeeding or discontinue the medication. This decision should take into account the importance of the drug to the mother's medical care.

Patients are encouraged to speak with their healthcare team about the safest way to feed their infant while receiving treatment.

Dosage Forms

NPlate is available as a sterile powder in a single-dose vial. It does not contain any preservatives. This powder must be reconstituted, or mixed with sterile water, to create a liquid solution before it is used.

Administration

The medication is administered as a subcutaneous injection. This type of injection is given into the fatty tissue just beneath the skin. It is usually administered by a healthcare provider.

FDA Approval History

Nplate (romiplostim) received its initial FDA approval in August 2008. It was the first medication in the peptibody class approved for the treatment of chronic immune thrombocytopenia (ITP).

Approved Indications

The FDA has approved Nplate for the following specific uses:

• Treatment of low blood platelet counts in adults with immune thrombocytopenia (ITP) when other treatments, such as corticosteroids or surgery to remove the spleen, have not worked well enough.
• Treatment of ITP in pediatric patients 1 year of age and older who have had the condition for at least 6 months and have not responded to other therapies.
• To increase survival in adults and children, including newborns, who have been exposed to high doses of radiation (Acute Radiation Syndrome).

Regulatory History and Safety Monitoring

At the time of its initial release, Nplate was subject to a Risk Evaluation and Mitigation Strategy (REMS) program called NEXUS. This program was designed to track and manage serious risks, such as bone marrow changes and blood clots. In 2011, the FDA removed the REMS requirement, concluding that the risks were well-understood and could be managed through standard prescribing information and physician oversight.

Regulatory authorities monitor Nplate for several safety concerns, including the risk of blood clots if platelet counts rise too high and the potential for bone marrow fibers (reticulin) to increase. The FDA also notes that Nplate is not approved for treating myelodysplastic syndromes (MDS) due to the risk of progression to acute myeloid leukemia.

Factors Affecting Cost

The price you pay for NPlate can vary based on several variables:

• Insurance Plan: Your specific health insurance plan determines your out-of-pocket expenses, such as copayments or coinsurance. Many plans require prior authorization before they will cover the cost of NPlate.
• Dosage: NPlate is a weight-based medication. Because the dose is adjusted based on your platelet count and body weight, the amount of medication used—and therefore the cost—may change over time.
• Administration Fees: Since NPlate is typically administered by a healthcare provider in a clinic or office, you may incur costs related to the visit and the injection procedure itself.

Financial Assistance

Because NPlate is a specialty biologic medication, it can be expensive. There are options available to help manage these costs:

• Manufacturer Support: The drug manufacturer often provides a copay card for patients with commercial insurance to help lower out-of-pocket costs.
• Patient Assistance Programs: For those who are uninsured or have limited coverage, programs may be available to provide the medication at a lower cost or for free, depending on financial eligibility.
• Medicare and Medicaid: Coverage is often available through government programs, though specific costs will depend on your individual plan details.

It is best to speak with your pharmacist or insurance provider to get a precise estimate of your costs for NPlate.